106 related articles for article (PubMed ID: 26630704)
1. Dual HER2 Blockade in Non-Small Cell Lung Cancer Harboring a HER2 Mutation.
Mar N; Vredenburgh JJ
Conn Med; 2015 Oct; 79(9):531-5. PubMed ID: 26630704
[TBL] [Abstract][Full Text] [Related]
2. Targeting HER2 in the treatment of non-small cell lung cancer.
Mar N; Vredenburgh JJ; Wasser JS
Lung Cancer; 2015 Mar; 87(3):220-5. PubMed ID: 25601485
[TBL] [Abstract][Full Text] [Related]
3. Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer.
Kuyama S; Hotta K; Tabata M; Segawa Y; Fujiwara Y; Takigawa N; Kiura K; Ueoka H; Eguchi K; Tanimoto M
J Thorac Oncol; 2008 May; 3(5):477-82. PubMed ID: 18448999
[TBL] [Abstract][Full Text] [Related]
4. HER2 and lung cancer.
Landi L; Cappuzzo F
Expert Rev Anticancer Ther; 2013 Oct; 13(10):1219-28. PubMed ID: 24134423
[TBL] [Abstract][Full Text] [Related]
5. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
Cappuzzo F; Varella-Garcia M; Shigematsu H; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Gregorc V; Toschi L; Franklin WA; Crino L; Gazdar AF; Bunn PA; Hirsch FR
J Clin Oncol; 2005 Aug; 23(22):5007-18. PubMed ID: 16051952
[TBL] [Abstract][Full Text] [Related]
6. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Mazières J; Peters S; Lepage B; Cortot AB; Barlesi F; Beau-Faller M; Besse B; Blons H; Mansuet-Lupo A; Urban T; Moro-Sibilot D; Dansin E; Chouaid C; Wislez M; Diebold J; Felip E; Rouquette I; Milia JD; Gautschi O
J Clin Oncol; 2013 Jun; 31(16):1997-2003. PubMed ID: 23610105
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?
Dongiovanni D; Daniele L; Barone C; Dongiovanni V; Fissore C; Sapino A; Macrì L; Bussolati G; Buffoni L; Gaspari F; Grillo R; Birocco N; Addeo A; Ciuffreda L; Schena M
Lung Cancer; 2008 Jul; 61(1):73-81. PubMed ID: 18243402
[TBL] [Abstract][Full Text] [Related]
8. The force of HER2 - A druggable target in NSCLC?
Jebbink M; de Langen AJ; Boelens MC; Monkhorst K; Smit EF
Cancer Treat Rev; 2020 Jun; 86():101996. PubMed ID: 32135383
[TBL] [Abstract][Full Text] [Related]
9. Silver-enhanced in situ hybridization for determination of EGFR copy number alterations in non-small cell lung cancer.
Wulf MA; Bode B; Zimmermann D; Rufibach K; Weder W; Moch H; Soltermann A; Tischler V
Am J Surg Pathol; 2012 Dec; 36(12):1801-8. PubMed ID: 23154768
[TBL] [Abstract][Full Text] [Related]
10. HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin.
Heinmöller P; Gross C; Beyser K; Schmidtgen C; Maass G; Pedrocchi M; Rüschoff J
Clin Cancer Res; 2003 Nov; 9(14):5238-43. PubMed ID: 14614004
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
Ross HJ; Blumenschein GR; Aisner J; Damjanov N; Dowlati A; Garst J; Rigas JR; Smylie M; Hassani H; Allen KE; Leopold L; Zaks TZ; Shepherd FA
Clin Cancer Res; 2010 Mar; 16(6):1938-49. PubMed ID: 20215545
[TBL] [Abstract][Full Text] [Related]
12. Investigation of HER2 overexpression in non-small cell lung cancer.
Ugocsai K; Mándoky L; Tiszlavicz L; Molnár J
Anticancer Res; 2005; 25(4):3061-6. PubMed ID: 16080566
[TBL] [Abstract][Full Text] [Related]
13. HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy.
Junker K; Stachetzki U; Rademacher D; Linder A; Macha HN; Heinecke A; Müller KM; Thomas M
Lung Cancer; 2005 Apr; 48(1):59-67. PubMed ID: 15777971
[TBL] [Abstract][Full Text] [Related]
14. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.
Cappuzzo F; Bemis L; Varella-Garcia M
N Engl J Med; 2006 Jun; 354(24):2619-21. PubMed ID: 16775247
[No Abstract] [Full Text] [Related]
15. The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy.
Nicoś M; Krawczyk P; Mlak R; Sawicki M; Jarosz B; Powrózek T; Milanowski P; Trojanowski T; Milanowski J
Pneumonol Alergol Pol; 2013; 81(4):294-7. PubMed ID: 23744164
[TBL] [Abstract][Full Text] [Related]
16. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
Willmore-Payne C; Holden JA; Layfield LJ
Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
[TBL] [Abstract][Full Text] [Related]
17. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer.
Hirsch FR; Varella-Garcia M; Cappuzzo F
Oncogene; 2009 Aug; 28 Suppl 1():S32-7. PubMed ID: 19680294
[TBL] [Abstract][Full Text] [Related]
19. Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea.
Lee K; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Cancer Res Treat; 2020 Jan; 52(1):292-300. PubMed ID: 31345011
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
